Dr. Mohammad Alfatah completed the Master in Biotechnology at Jamia Hamdard University, New Delhi, India. He was awarded Council of Scientific and Industrial Research and Indian Council of Medical Research fellowships to pursue the research. He studied Doctor of Philosophy at the CSIR-Institute of Microbial Technology, Chandigarh and received his PhD degree in Biological Sciences from Jawaharlal Nehru University, New Delhi, India. He joined the A*STAR Bioinformatics Institute (BII) in 2015 as a postdoctoral research fellow. He was awarded the 2020 A*STAR Career Development Award (CDA) and currently leading his group, Aging Biology Intervention Research, in BII since April 2021.
Alfatah Lab goal is to discover novel interventions for prolonging disease-free life through leading research in aging biology. Aging is the biggest risk factor for various human pathologies, including cancer, neurodegeneration, cardiovascular disease and diabetes. Alfatah Lab identifies antiaging compounds by screening the small molecules, natural products, and FDA-approved drugs repurposing. This includes developing robust high throughput screening methods, discovery-driven approaches integrating with functional and chemical genetics profiling, identification of genes, proteins, and biological processes involved in the biology of aging. The novel antiaging compounds will be utilized in several applications, including food supplements and pharmaceutical ingredients, to delay aging and prolong healthspan.
Alfatah Lab's other major focus is human fungal pathogens. Aging is associated with an increase in the prevalence of invasive fungal infections caused mainly by pathogenic yeast species Candida that threatens the health quality late in life. The infectious research program aims to develop and establish innovative experimental technologies integrated with clinical requirements to identify potent antifungal drugs. In addition, the studies investigate the molecular pathways underpinning fungal pathogenesis to use this knowledge to develop novel therapeutic strategies to treat invasive fungal infections.